NERV · Minerva Neurosciences, Inc.

Track NERV — free

$5.14 +0.01 (+0.19%)

Russell 2000 member Rebalance outlook locked

Market Cap

$244.94M

47.75M

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 7, 2026

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Neutral Sentiment Bullish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 14.5 · calm Equity put/call 0.39

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +1%

above

Price vs 50-day avg +14%

above

RSI (14) 60

neutral

MACD trend Positive

52-week position 51%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return +28%

trailing

6-month return −15%

trailing

YTD return +28%

this year

Relative strength −29%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $5 › 200d $5 — 200d above 50d

Institutional flow Accumulating

+23% holders QoQ · +24 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.68% of float · ▼ -28.3% MoM · 11.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

58 holders — near 3-yr high, broad support

Squeeze score 58

elevated · 0–100

Fundamentals

Weak

EPS growth −18347%

Y/Y

Free cash flow $-13.5M

Balance sheet $73.9M

net cash

Quant / Vol

risk profile

Very High

Volatility 171%

annualized · 1-yr

Max drawdown −51%

past year

ATR 7.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

0 · 4 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+1% Bullish

Price vs 50-day avg

+14% Bullish

RSI (14)

60 Neutral

MACD trend

Positive Bullish

52-week position

51% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $5 › 200d $5 — 200d above 50d

Institutional flow Accumulating

+23% holders QoQ · +24 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.68% of float · ▼ -28.3% MoM · 11.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

58 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $5 · 51% Range high $8

vs 200-day avg +1% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted net income (loss) – non-GAAP non-GAAP	-7.81M	Three Months Ended June 30, 2026 filing	—
GAAP → non-GAAP reconciliation GAAP Net income (loss) – GAAP 17.47M +2.27M Stock-based compensation expense -27.55M Changes in fair value of the warrant liability = Adjusted net income (loss) – non-GAAP -7.81M
non-GAAP adjusted net loss non-GAAP	$7.3M	three months ended March 31, 2026	—
non-GAAP adjusted net loss per share non-GAAP	$0.17	three months ended March 31, 2026	—
non-GAAP total liabilities non-GAAP	$4.5M	three months ended March 31, 2026	—
GAAP → non-GAAP reconciliation GAAP Total liabilities - GAAP 343.08M -278.6M Warrant liability -60M Liability related to the sale of future royalties = Total liabilities - non-GAAP 4.48M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NERV Minerva Neurosciences, Inc. this stock	$244.94M	+27.6%	—	—	3.7%
VRTX Vertex Pharmaceuticals Inc / Ma	$138.72B	+20.8%	+46.2%	31.9	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$81.27B	+4.6%	+20.8%	20.2	2.3%
ARGX Argenx SE	$65.12B	+25.9%	—	—	1.9%
CSLLY Csl Ltd	$59.92B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 88.6%
Net QoQ: +4.0M sh
Top holder: FEDERATED HERMES, INC.

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

1.8M

Days to cover: 11.8d
Change: -691.4K sh

View

Short Volume

Short vol %

59%

As of: Aug 27, 2026

Short Total

View

Fails to Deliver

FTD shares

1.7K

Value: $7.4K
As of: Jul 20, 2026

View

Off-Exchange

Off-exchange %

28.1%

Week of: Jul 20, 2026

Off-exch Lit

View

Financials

Revenue (FY)

Net income (FY): $-293.4M
EPS diluted: $-34.67

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 12, 2026
This year: 14

View

Proposed Sales

Value

$158.7K

Shares: 19.8K
Filed: Mar 31, 2026

View

Exempt Offerings

Offering

$20.0M

Filed: Jul 3, 2023

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 8, 2026

Last call: Jun 4, 2026

View

Investor Relations

Upcoming events

View

Performance

Raw-price comparisons begin at the captured split on Jun 21, 2022; windows that need an earlier baseline remain unavailable.

	5D	20D	120D	MTD	YTD
NERV	+7.1%	+27.6%	-14.6%	+28.9%	+27.6%
SPY	+1.1%	+4.0%	+14.7%	+3.2%	+13.1%
vs SPY	+6.0%	+23.6%	-29.3%	+25.7%	+14.5%

Key facts CIK 1598646 CUSIP 603380205 13F (30d) 55 filings 53 filers Visit website Investor relations

NERV · Minerva Neurosciences, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance